ESPR vs FLT
Esperion Therapeutics Inc (ESPR) versus FLT (FLT) — a side-by-side from cached financials, not a winner call.
Esperion Therapeutics Inc (ESPR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
FLT (FLT) common stock.
Latest reported ESPR revenue for 2025-12-31 was $403.1M. Net income was -$22.7M. Revenue was up 21.3% from 2024-12-31 to 2025-12-31. ESPR currently screens at market cap $816.9M.
FLT does not have a complete income-statement cache yet.
ESPR currently screens at market cap $816.9M.
Not investment advice. Open the ESPR and FLT stock pages for the full models.
Not investment advice.